NCT06154408 - Evaluating the Impact of Omega-3 Fatty Acid Supplementation (Soloways™) on Lipid Profiles in Adults With PPARG Polymorphisms | Biotech Hunter

Enrollment

102

Participants

Timeline

Start Date

February 10, 2022

Primary Completion Date

July 1, 2022

Study Completion Date

November 1, 2022

Conditions

LDL HyperlipoproteinemiaLow-Density-Lipoprotein-Type [LDL] HyperlipoproteinemiaTriglyceride Storage Type I or II Disease

Interventions

DIETARY_SUPPLEMENT

omega-3 fatty acids

The active treatment, supplied by Soloways, LLC., contained omega-3 fatty acids (1000 mg of fish oil, of which 600 mg were eicosapentaenoic acid and 300 mg docosahexaenoic acid) per capsule. The subjects will take 2 capsules daily.

DIETARY_SUPPLEMENT

Placebo

placebo capsules identical in appearance, matched for color coating, shape, and size with omega-3 fatty acids capsule

Trial Locations (1)

630090

Center of New Medical Technologies, Novosibirsk